Print

Galapagos NV (GLPG.BR) to Present Phase 1 Data on FFA2 Antagonist GLPG0974 at UEG Week in Berlin  
10/16/2013 10:01:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Galapagos NV (Euronext: GLPG) announced today that the Company will present in vitro and Phase 1 data showing potent and selective inhibition of FFA2 by GLPG0974 at the United European Gastroenterology Week, taking place from 12 to 16 October 2013 in Berlin, Germany. "The FFA2 antagonist GLPG0974: Opportunity to treat neutrophil-driven inflammation" will be presented on 16 October from 9 am to 2 pm CET and has been granted Poster of Excellence designation from the UEG Week Scientific Committee. The poster is also now available online at www.glpg.com.

Help employers find you! Check out all the jobs and post your resume.

//-->